NCT04883281 2026-03-18
DARTBOARD
University of Texas Southwestern Medical Center
Phase 2 Completed
Clinical Trials
75 trialsNCT02031250 2026-03-02
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03953976 2026-02-19
INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT02296684 2026-01-15
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Completed
NCT02921256 2025-12-04
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01602666 2025-11-20
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT01991977 2025-10-20
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT02186847 2025-10-09
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
NCT02254278 2025-10-09
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NRG Oncology
Phase 2 Completed
NCT03984357 2025-07-17
PLATINUM
Sun Yat-sen University
Phase 2 Completed
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT04003246 2025-03-21
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT04380337 2025-02-25
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
Phase 2 Completed
NCT02000050 2025-01-30
COLORE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT02281955 2025-01-07
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02573493 2024-12-27
APA
Washington University School of Medicine
Phase 2 Completed
NCT01530997 2024-11-13
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02609503 2024-11-05
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04895345 2024-09-26
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT03521570 2024-09-19
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Emory University
Phase 2 Completed
NCT00720304 2024-08-22
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02776163 2024-07-30
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT03077243 2024-05-02
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04577638 2024-02-07
AIRING
Center Eugene Marquis
Phase 2 Completed
NCT02073968 2024-01-25
PAINT
Albert Einstein College of Medicine
Phase 2 Completed
NCT03535259 2024-01-10
SIRAHCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT03894891 2023-12-20
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00895622 2023-09-08
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02427841 2023-09-06
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03242824 2023-03-14
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
Mayo Clinic
Phase 2 Completed
NCT01730950 2022-12-29
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01389050 2022-10-07
High Precision RT For Soft-Tissue Sarcoma
University Health Network, Toronto
Phase 2 Completed
NCT04005170 2022-08-23
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT01062425 2022-07-26
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01236547 2022-07-19
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03067610 2022-03-17
INFIELD
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02562599 2022-02-22
Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin
Hubei Cancer Hospital
Phase 2 Completed
NCT02508389 2021-09-20
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT02864849 2021-07-23
Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT01566435 2020-10-01
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00833261 2020-08-21
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02776137 2020-08-19
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT00721513 2020-04-07
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT03211117 2020-03-25
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Mayo Clinic
Phase 2 Completed
NCT00188877 2019-12-02
Intensity Modulated Radiation Therapy for Head and Neck Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01661088 2019-11-13
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
University of Michigan Rogel Cancer Center
Phase 2 Completed